Rick Matthews/LikedIn
Mar 9, 2026, 13:49
Rick Matthews: Looking Beyond Clot Clearance in Long-Term Management After DVT
Rick Matthews, Senior Vascular Consultant at Argon Medical Devices, Inc., shared on LinkedIn:
”We talk a lot about ‘clearing clot today’ with modern mechanical thrombectomy/PMT options, but the long game is what patients live with: recurrent ipsilateral DVT risk, valve injury, chronic outflow obstruction, and structured follow-up.
Are you routinely documenting Villalta at 3–6 months after DVT (and repeating at ~12 months), or is it still inconsistent across services?
PTS symptoms often reflect the net effect of obstruction plus reflux plus microvascular injury—so the pathway has to be stepwise.
My simple escalation triggers (baked into any VTE program):
- Villalta ≥10 / meaningful functional limitation
- Venous claudication
- Skin changes or ulcer
- New/worsening swelling – rule out recurrent DVT first”
Stay updated with Hemostasis Today.
-
Jun 13, 2026, 18:25Miguel Gómez Álvarez: Reviewing Inflammation, Transplantation, and Gene Therapy in Hemoglobinopathies
-
Jun 13, 2026, 18:24Ana Pedrero Gil: Why Factor XIII Deficiency Is Often Overlooked During Acute Bleeding
-
Jun 13, 2026, 18:23Tobias Degsell: Building Stronger Bridges Across Disciplines, Countries, and Perspectives at EHA 2026
-
Jun 13, 2026, 18:22Haemoglobinopathies, Innovation, Patient Experience, and Equitable Access at EHA 2026 – TIF
-
Jun 13, 2026, 18:21Thomas Stauch: Discussing the Future of ITP Research and Patient Care
-
Jun 13, 2026, 17:11Kim De Keersmaecker: Advancing Hematology Through Shared Expertise at EHA 2026
-
Jun 13, 2026, 17:03Nour Al-Mozain: The Evolving Role of Apheresis Across Clinical Practice
-
Jun 13, 2026, 16:45Sarah Hendry: A Big Day for Gene Therapy Research at EHA 2026
-
Jun 13, 2026, 16:43Akshat Jain: Bridging Innovation and Access in Hematology at EHGCON 2026